Symbols / XBIO $3.01 +6.74% Xenetic Biosciences, Inc.
XBIO Chart
About
Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing immune-oncology technologies to treat cancers. Its DNase technology targets neutrophil extracellular traps (NETS), which are involved in cancer growth, metastasis, and progression, and contribute to immunotherapy, chemotherapy, and radiotherapy resistance. The company's product pipeline includes XBIO-015 for the treatment of pancreatic carcinoma and solid tumors; XBIO-020 for the treatment of solid tumors; and ErepoXen, which uses PolyXen platform technology for the treatment of anemia in chronic kidney disease (CKD) patients. It has a sublicensing agreement with Takeda Pharmaceutical Co. Ltd, as well as various research, development, license and supply agreements with Serum Institute of India, PJSC Pharmsynthez, and SynBio, LLC. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.90M |
| Enterprise Value | -986.10K | Income | -2.68M | Sales | 2.98M |
| Book/sh | 3.23 | Cash/sh | 3.44 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | -4.56 | PEG | — |
| P/S | 2.32 | P/B | 0.93 | P/C | — |
| EV/EBITDA | — | EV/Sales | -0.33 | Quick Ratio | 8.14 |
| Current Ratio | 8.32 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.58 | EPS next Y | -0.66 | EPS Growth | — |
| Revenue Growth | 18.10% | Earnings | 2026-03-12 17:00 | ROA | -23.21% |
| ROE | -40.00% | ROIC | — | Gross Margin | 100.00% |
| Oper. Margin | -81.30% | Profit Margin | -90.07% | Shs Outstand | 2.29M |
| Shs Float | 1.88M | Short Float | 1.89% | Short Ratio | 1.83 |
| Short Interest | — | 52W High | 13.93 | 52W Low | 1.90 |
| Beta | — | Avg Volume | 24.95K | Volume | 12.27K |
| Target Price | — | Recom | None | Prev Close | $2.82 |
| Price | $3.01 | Change | 6.74% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$3.01
Latest analyst target
3. DCF / Fair value
$-10.60
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.01
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-09 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-03-20 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-12-05 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2024-11-22 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2024-08-20 | reit | HC Wainwright & Co. | — → Neutral | — |
| 2023-05-16 | down | HC Wainwright & Co. | Buy → Neutral | — |
- Cancer biotech Xenetic grows Takeda royalties to $3M, trims costs - Stock Titan Fri, 13 Mar 2026 07
- XBIO.WS (Xenetic Biosciences) PB Ratio : (As of Apr. 04, 2026) - GuruFocus Sat, 04 Apr 2026 10
- XBIO PE Ratio & Valuation, Is XBIO Overvalued - Intellectia AI Sat, 04 Apr 2026 16
- XBIO Shares Skyrocket: Exploring the Surge - StocksToTrade Wed, 08 Oct 2025 07
- symbol__ Stock Quote Price and Forecast - CNN Wed, 14 Feb 2024 13
- [8-K] Xenetic Biosciences, Inc. Reports Material Event - Stock Titan Fri, 13 Mar 2026 07
- MAGA Stocks Undercard: MYSE, XBIO, ATON, ACXP, RDZN - Innovators Driving Next Tech, Blockchain, AI Wave - More Stocks Inside - marketscreener.com hu, 09 Oct 2025 07
- Micron, Galecto And Xenetic Lead This Week's Benzinga Stock Ranking Surges - benzinga.com Fri, 10 Oct 2025 07
- Xenetic Biosciences (XBIO) Stock Skyrockets – Is the Biotech’s 2025 Rally for Real? - TechStock² Wed, 08 Oct 2025 07
- XBIO Forecast — Price Prediction for 2026. Should I Buy XBIO? - Intellectia AI Mon, 02 Jun 2025 06
- Xenetic Biosciences, Inc. (XBIO) Stock Price, News, Quote & History - ca.finance.yahoo.com hu, 18 May 2017 10
- Xenetic Biosciences Stock Price Forecast. Should You Buy XBIO? - StockInvest.us ue, 01 Dec 2020 16
- XBIO SEC Filings - Xenetic Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan Sat, 07 Mar 2026 10
- Xenetic Biosciences Prices $4.5 Million Stock Offering; Shares Fall - marketscreener.com Fri, 10 Oct 2025 07
- NIO Inc. American depositary shares each representing one Class A (NIO) Stock Price | Live Quotes & Charts | NYSE - StocksToTrade Fri, 19 Sep 2025 16
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
2.98
+19.04%
|
2.50
-1.56%
|
2.54
+48.80%
|
1.71
|
| Operating Revenue |
|
2.98
+19.04%
|
2.50
-1.56%
|
2.54
+48.80%
|
1.71
|
| Operating Expense |
|
5.81
-13.33%
|
6.70
-4.97%
|
7.06
-16.25%
|
8.42
|
| Research And Development |
|
3.07
-6.78%
|
3.29
-5.91%
|
3.49
-26.75%
|
4.77
|
| Selling General And Administration |
|
2.75
-19.64%
|
3.42
-4.06%
|
3.56
-2.55%
|
3.65
|
| General And Administrative Expense |
|
2.75
-19.64%
|
3.42
-4.06%
|
3.56
-2.55%
|
3.65
|
| Other Gand A |
|
2.75
-19.64%
|
3.42
-4.06%
|
3.56
-2.55%
|
3.65
|
| Total Expenses |
|
5.81
-13.33%
|
6.70
-4.97%
|
7.06
-16.25%
|
8.42
|
| Operating Income |
|
-2.83
+32.58%
|
-4.20
+6.89%
|
-4.52
+32.78%
|
-6.72
|
| Total Operating Income As Reported |
|
-2.83
+32.58%
|
-4.20
+6.89%
|
-4.52
+32.78%
|
-6.72
|
| EBITDA |
|
-2.83
+32.58%
|
-4.20
+6.89%
|
-4.52
+32.51%
|
-6.69
|
| Normalized EBITDA |
|
-2.83
+32.58%
|
-4.20
+6.89%
|
-4.52
+32.51%
|
-6.69
|
| Reconciled Depreciation |
|
—
|
—
|
0.00
-100.00%
|
0.03
|
| EBIT |
|
-2.83
+32.58%
|
-4.20
+6.89%
|
-4.52
+32.78%
|
-6.72
|
| Total Unusual Items |
|
—
|
—
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
—
|
| Special Income Charges |
|
—
|
—
|
—
|
—
|
| Impairment Of Capital Assets |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-2.68
+32.31%
|
-3.96
+4.22%
|
-4.13
+36.90%
|
-6.55
|
| Pretax Income |
|
-2.68
+32.31%
|
-3.96
+4.22%
|
-4.13
+36.90%
|
-6.55
|
| Net Non Operating Interest Income Expense |
|
0.15
-40.77%
|
0.25
-29.77%
|
0.36
+112.83%
|
0.17
|
| Net Interest Income |
|
0.15
-40.77%
|
0.25
-29.77%
|
0.36
+112.83%
|
0.17
|
| Interest Income Non Operating |
|
0.15
-40.77%
|
0.25
-29.77%
|
0.36
+112.83%
|
0.17
|
| Interest Income |
|
0.15
-40.77%
|
0.25
-29.77%
|
0.36
+112.83%
|
0.17
|
| Other Income Expense |
|
0.01
+200.30%
|
-0.01
-122.49%
|
0.03
+1689.23%
|
-0.00
|
| Other Non Operating Income Expenses |
|
0.01
+200.30%
|
-0.01
-122.49%
|
0.03
+1689.23%
|
-0.00
|
| Tax Provision |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-2.68
+32.31%
|
-3.96
+4.22%
|
-4.13
+36.90%
|
-6.55
|
| Net Income From Continuing Operation Net Minority Interest |
|
-2.68
+32.31%
|
-3.96
+4.22%
|
-4.13
+36.90%
|
-6.55
|
| Net Income From Continuing And Discontinued Operation |
|
-2.68
+32.31%
|
-3.96
+4.22%
|
-4.13
+36.90%
|
-6.55
|
| Net Income Continuous Operations |
|
-2.68
+32.31%
|
-3.96
+4.22%
|
-4.13
+36.90%
|
-6.55
|
| Normalized Income |
|
-2.68
+32.31%
|
-3.96
+4.22%
|
-4.13
+36.90%
|
-6.55
|
| Net Income Common Stockholders |
|
-2.68
+32.31%
|
-3.96
+4.22%
|
-4.13
+36.90%
|
-6.55
|
| Diluted EPS |
|
-1.58
+38.52%
|
-2.57
+5.17%
|
-2.71
+41.21%
|
-4.61
|
| Basic EPS |
|
-1.58
+38.52%
|
-2.57
+5.17%
|
-2.71
+41.21%
|
-4.61
|
| Basic Average Shares |
|
1.70
+10.40%
|
1.54
+0.86%
|
1.53
+7.44%
|
1.42
|
| Diluted Average Shares |
|
1.70
+10.40%
|
1.54
+0.86%
|
1.53
+7.44%
|
1.42
|
| Diluted NI Availto Com Stockholders |
|
-2.68
+32.31%
|
-3.96
+4.22%
|
-4.13
+36.90%
|
-6.55
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
8.36
+21.19%
|
6.90
-34.92%
|
10.61
-27.96%
|
14.72
|
| Current Assets |
|
8.05
+22.20%
|
6.59
-31.29%
|
9.59
-29.78%
|
13.65
|
| Cash Cash Equivalents And Short Term Investments |
|
7.88
+27.87%
|
6.17
-31.36%
|
8.98
-31.41%
|
13.10
|
| Cash And Cash Equivalents |
|
7.88
+27.87%
|
6.17
-31.36%
|
8.98
-31.41%
|
13.10
|
| Cash Financial |
|
7.88
+27.87%
|
6.17
-31.36%
|
8.98
-31.41%
|
13.10
|
| Prepaid Assets |
|
—
|
—
|
—
|
0.56
|
| Other Current Assets |
|
0.17
-60.59%
|
0.42
-30.12%
|
0.60
+8.58%
|
0.56
|
| Total Non Current Assets |
|
0.31
+0.00%
|
0.31
-69.17%
|
1.02
-4.55%
|
1.07
|
| Net PPE |
|
—
|
—
|
—
|
—
|
| Gross PPE |
|
—
|
—
|
—
|
—
|
| Accumulated Depreciation |
|
—
|
—
|
—
|
—
|
| Machinery Furniture Equipment |
|
—
|
—
|
—
|
—
|
| Other Non Current Assets |
|
0.31
+0.00%
|
0.31
-69.17%
|
1.02
-4.55%
|
1.07
|
| Total Liabilities Net Minority Interest |
|
0.97
+8.25%
|
0.89
+10.46%
|
0.81
-24.56%
|
1.07
|
| Current Liabilities |
|
0.97
+8.25%
|
0.89
+10.46%
|
0.81
-24.56%
|
1.07
|
| Payables And Accrued Expenses |
|
0.94
+9.78%
|
0.86
+12.97%
|
0.76
-26.31%
|
1.03
|
| Payables |
|
0.26
-8.99%
|
0.28
+17.76%
|
0.24
-16.19%
|
0.29
|
| Accounts Payable |
|
0.26
-8.99%
|
0.28
+17.76%
|
0.24
-16.19%
|
0.29
|
| Current Accrued Expenses |
|
0.69
+19.01%
|
0.58
+10.75%
|
0.52
-30.21%
|
0.75
|
| Other Current Liabilities |
|
0.02
-30.20%
|
0.03
-29.12%
|
0.05
+20.79%
|
0.04
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Stockholders Equity |
|
7.40
+23.12%
|
6.01
-38.67%
|
9.80
-28.22%
|
13.65
|
| Common Stock Equity |
|
7.39
+23.13%
|
6.01
-38.68%
|
9.79
-28.22%
|
13.64
|
| Capital Stock |
|
0.00
+11.91%
|
0.00
+0.03%
|
0.00
-22.03%
|
0.00
|
| Common Stock |
|
0.00
+48.48%
|
0.00
+0.06%
|
0.00
+1.58%
|
0.00
|
| Preferred Stock |
|
0.00
-19.40%
|
0.00
+0.00%
|
0.00
-34.97%
|
0.00
|
| Share Issued |
|
2.29
+48.48%
|
1.54
+0.09%
|
1.54
+1.58%
|
1.52
|
| Ordinary Shares Number |
|
2.29
+48.56%
|
1.54
+0.09%
|
1.54
+1.58%
|
1.52
|
| Treasury Shares Number |
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
+0.07%
|
0.00
|
| Additional Paid In Capital |
|
212.29
+1.95%
|
208.23
+0.08%
|
208.05
+0.14%
|
207.77
|
| Retained Earnings |
|
-199.88
-1.36%
|
-197.19
-2.05%
|
-193.23
-2.19%
|
-189.10
|
| Gains Losses Not Affecting Retained Earnings |
|
0.25
+0.00%
|
0.25
+0.00%
|
0.25
+0.00%
|
0.25
|
| Treasury Stock |
|
5.28
+0.00%
|
5.28
+0.00%
|
5.28
+0.00%
|
5.28
|
| Other Equity Adjustments |
|
0.25
+0.00%
|
0.25
+0.00%
|
0.25
+0.00%
|
0.25
|
| Total Equity Gross Minority Interest |
|
7.40
+23.12%
|
6.01
-38.67%
|
9.80
-28.22%
|
13.65
|
| Total Capitalization |
|
7.40
+23.12%
|
6.01
-38.67%
|
9.80
-28.22%
|
13.65
|
| Working Capital |
|
7.08
+24.39%
|
5.69
-35.14%
|
8.78
-30.23%
|
12.58
|
| Invested Capital |
|
7.39
+23.13%
|
6.01
-38.68%
|
9.79
-28.22%
|
13.64
|
| Net Tangible Assets |
|
7.40
+23.12%
|
6.01
-38.67%
|
9.80
-28.22%
|
13.65
|
| Tangible Book Value |
|
7.39
+23.13%
|
6.01
-38.68%
|
9.79
-28.22%
|
13.64
|
| Preferred Stock Equity |
|
0.00
-19.40%
|
0.00
+0.00%
|
0.00
-34.97%
|
0.00
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-2.29
+18.84%
|
-2.82
+31.52%
|
-4.11
+11.46%
|
-4.65
|
| Cash Flow From Continuing Operating Activities |
|
-2.29
+18.84%
|
-2.82
+31.52%
|
-4.11
+11.46%
|
-4.65
|
| Net Income From Continuing Operations |
|
-2.68
+32.31%
|
-3.96
+4.22%
|
-4.13
+36.90%
|
-6.55
|
| Depreciation Amortization Depletion |
|
—
|
—
|
0.00
-100.00%
|
0.03
|
| Depreciation |
|
—
|
—
|
0.00
-100.00%
|
0.03
|
| Depreciation And Amortization |
|
—
|
—
|
0.00
-100.00%
|
0.03
|
| Other Non Cash Items |
|
—
|
—
|
—
|
1.79
|
| Stock Based Compensation |
|
0.06
-62.29%
|
0.17
-39.31%
|
0.28
-44.65%
|
0.51
|
| Asset Impairment Charge |
|
—
|
—
|
—
|
—
|
| Deferred Tax |
|
—
|
—
|
—
|
—
|
| Deferred Income Tax |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
0.33
-66.07%
|
0.97
+469.58%
|
-0.26
+38.43%
|
-0.43
|
| Change In Prepaid Assets |
|
0.26
+40.57%
|
0.18
+481.02%
|
-0.05
+53.99%
|
-0.10
|
| Change In Payables And Accrued Expense |
|
0.07
-12.89%
|
0.08
+132.13%
|
-0.26
+24.25%
|
-0.35
|
| Change In Payable |
|
0.07
-12.89%
|
0.08
+132.13%
|
-0.26
+24.25%
|
-0.35
|
| Change In Account Payable |
|
0.07
-12.89%
|
0.08
+132.13%
|
-0.26
+24.25%
|
-0.35
|
| Change In Other Current Assets |
|
0.00
-100.00%
|
0.70
+1350.07%
|
0.05
+94.32%
|
0.03
|
| Investing Cash Flow |
|
—
|
—
|
0.00
+100.00%
|
-0.50
|
| Cash Flow From Continuing Investing Activities |
|
—
|
—
|
0.00
+100.00%
|
-0.50
|
| Capital Expenditure |
|
—
|
—
|
—
|
-0.50
|
| Net Intangibles Purchase And Sale |
|
—
|
—
|
0.00
+100.00%
|
-0.50
|
| Purchase Of Intangibles |
|
—
|
—
|
0.00
+100.00%
|
-0.50
|
| Financing Cash Flow |
|
4.00
|
0.00
|
—
|
0.00
|
| Cash Flow From Continuing Financing Activities |
|
4.00
+400471400.00%
|
0.00
|
—
|
0.00
|
| Net Common Stock Issuance |
|
4.00
+400471400.00%
|
0.00
|
—
|
0.00
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
—
|
0.00
|
| Net Other Financing Charges |
|
—
|
-0.00
|
—
|
—
|
| Changes In Cash |
|
1.72
+160.98%
|
-2.82
+31.52%
|
-4.11
+20.06%
|
-5.15
|
| Beginning Cash Position |
|
6.17
-31.36%
|
8.98
-31.41%
|
13.10
-28.21%
|
18.24
|
| End Cash Position |
|
7.88
+27.87%
|
6.17
-31.36%
|
8.98
-31.41%
|
13.10
|
| Free Cash Flow |
|
-2.29
+18.84%
|
-2.82
+31.52%
|
-4.11
+20.06%
|
-5.15
|
| Interest Paid Supplemental Data |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Common Stock Issuance |
|
4.00
+400471400.00%
|
0.00
|
—
|
0.00
|
| Issuance Of Capital Stock |
|
4.00
+400471400.00%
|
0.00
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-13 View
- 10-K2026-03-12 View
- 8-K2026-01-09 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 42026-01-05 View
- 8-K2025-12-11 View
- 8-K2025-11-13 View
- 10-Q2025-11-12 View
- 8-K2025-10-14 View
- 8-K2025-08-13 View
- 10-Q2025-08-12 View
- 8-K2025-05-14 View
- 10-Q2025-05-13 View
- 8-K2025-04-10 View
- 8-K2025-03-19 View
- 10-K2025-03-18 View
- 42024-12-13 View
- 42024-12-13 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|